The International Menopause Society - SFOG

More documents

Recommendations

Info

Change in density during different treatments. 45 40 35 30 25 20 Baseline 6 months 15 10 5 0 E2/NETA n=43 Tibolone n=49 Black Cohosh n=64 Placebo n=53
Tibolone and BC risk in healthy women MWS RR: 1.45 CI: 1.25 – 1.68 GPRD RR: 0.86 CI: 0.65 – 1.13 LIFT RCT RH: 0.32 CI: 0.13 – 0.80 Lancet 2003 ; 362: 1160 BJOG 2008; 115: 169 N Engl J Med 2008; 359: 697
Page 1 and 2: HRT idag och i morgon: mot lägre d
Page 3 and 4: jan-00 jul-00 jan-01 jul-01 jan-02
Page 5 and 6: Djup förtroendekris Risker och sä
Page 7 and 8: Postmenopausal Hormone Therapy: an
Page 9 and 10: ERT vs HRT Progestin related side e
Page 11 and 12: No uterus no problem !
Page 14 and 15: Progesterone and progestins can rea
Page 16 and 17: Secreted VEGF in T47-D cells in res
Page 18 and 19: Breast stimulation a class effect
Page 20 and 21: HRT utan bröstpåverkan Är det m
Page 22 and 23: change in density from different pr
Page 24 and 25: Vaginal Maturation Index Placebo 10
Page 26 and 27: Mean number NUMBER OF MODERATE TO S
Page 28 and 29: Mean breast density (%) Mammographi
Page 30: Testosterone addition inhibits estr
Page 35 and 36: MLS 10 µg LNG/day Mirena 20 µg LN
Page 37 and 38: Raloxifene
Page 39: BZA 20 mg/ CEE 0.45 mg a 2 year RCT
Page 42 and 43: Mammary Gland Branching in Ducts fr
Page 44 and 45: Options for breast safety Regim VMS

The International Menopause Society - SFOG

Create successful ePaper yourself

Delete template?

Save as template?